Abstract Background Direct oral anticoagulants (DOACs) have emerged as safe and
effective alternatives to Vitamin-K antagonists for treatment and prevention of arterial and …

Background: General consumers can now easily access drug information and quickly check
for potential drug-drug interactions (PDDIs) through mobile health (mHealth) apps. With …

Drug-drug interaction (DDI) is a change in the effect of a drug when patient takes another
drug. Characterizing DDIs is extremely important to avoid potential adverse drug reactions …

Although potential drug–drug interactions (PDDIs) are a significant source of preventable
drug-related harm, there is currently no single complete source of PDDI information. In the …

Introduction: Medication error is unintentional and can be reduced by reducing the risk
factors. Patients suffering from chronic diseases are at an increased risk of medication …

Purpose Due to polypharmacy and the rising popularity of complementary and alternative
medicines (CAM), oncology patients are particularly at risk of drug–drug interactions (DDI) or …

Introduction There is an increased risk of potential drug–drug interactions (pDDIs) in
critically ill patients based on the number of drugs received. The occurrence of pDDIs and …

Purpose Recommendations for including drug–drug interactions (DDIs) in clinical decision
support (CDS) are presented. Summary A conference series was conducted to improve CDS …

Objective The study sought to determine frequency and appropriateness of overrides of high-
priority drug-drug interaction (DDI) alerts and whether adverse drug events (ADEs) were …

Abstract Background and Objective Gilteritinib is a novel, highly selective tyrosine kinase
inhibitor approved in the USA, Canada, Europe, Brazil, Korea, and Japan for the treatment of …